JPMorgan Chase & Co. Increases Stock Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

JPMorgan Chase & Co. boosted its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 1.3% in the 3rd quarter, Holdings Channel.com reports. The fund owned 3,001,397 shares of the company’s stock after purchasing an additional 37,844 shares during the period. JPMorgan Chase & Co.’s holdings in Taysha Gene Therapies were worth $6,033,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Franklin Resources Inc. purchased a new position in shares of Taysha Gene Therapies during the 3rd quarter valued at $201,000. Barclays PLC grew its position in Taysha Gene Therapies by 356.0% during the third quarter. Barclays PLC now owns 247,280 shares of the company’s stock worth $513,000 after buying an additional 193,046 shares in the last quarter. Geode Capital Management LLC increased its stake in Taysha Gene Therapies by 23.7% in the 3rd quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock worth $7,163,000 after acquiring an additional 682,273 shares during the last quarter. Wellington Management Group LLP bought a new position in Taysha Gene Therapies in the 3rd quarter worth about $931,000. Finally, State Street Corp raised its holdings in shares of Taysha Gene Therapies by 4.5% in the 3rd quarter. State Street Corp now owns 3,469,068 shares of the company’s stock valued at $6,973,000 after acquiring an additional 150,647 shares in the last quarter. Institutional investors own 77.70% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on TSHA. JMP Securities reissued a “market outperform” rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Chardan Capital reissued a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a report on Thursday, November 14th. Canaccord Genuity Group lifted their price objective on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a research report on Monday, January 6th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Price Performance

Shares of NASDAQ:TSHA opened at $1.63 on Thursday. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. The stock has a market cap of $334.06 million, a PE ratio of 2.59 and a beta of 0.95. The company’s fifty day moving average is $2.13 and its 200 day moving average is $2.12. Taysha Gene Therapies, Inc. has a 52 week low of $1.19 and a 52 week high of $4.32.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.